Serum Biglycan as a Diagnostic Marker for Non-Alcoholic Steatohepatitis and Liver Fibrosis

Cengiz M., Yilmaz G., ÖZENİRLER MAYER S.

CLINICAL LABORATORY, cilt.67, sa.3, ss.804-820, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 67 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.7754/clin.lab.2020.200709
  • Dergi Adı: CLINICAL LABORATORY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.804-820
  • Anahtar Kelimeler: biglycan, liver fibrosis, NAFLD, NASH, non-invasive marker, MEAN PLATELET VOLUME, IDIOPATHIC THROMBOCYTOPENIC PURPURA, SIZE DEVIATION WIDTH, PREDICTORS, CHILDREN
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Non-alcoholic steatohepatitis (NASH) has risen in prevalence substantially through the years. Although course and progression of the disease are variable, fibrosis is the most important factor. We intended to explore utility of serum biglycan (BGN) in NASH and its capacity in anticipating liver fibrosis.